Glucose tolerance in fibromyalgia. Issue 46 (19th November 2021)

• Record Type: Journal Article
• Authors: Zetterman, Teemu; Markkula, Ritva; Kalso, Eija
• Editors: Tu., Wen-Jun
• Is Part Of: Medicine. Volume 100:Issue 46(2021)
• Page Start: e27803
• Publication Date: 2021-11-19
• Subjects: diabetes -- fibromyalgia -- glucose tolerance -- lactate -- pyruvate -- widespread pain; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000027803
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Objectives: Fibromyalgia (FM) patients have an increased risk for glucose metabolism disturbances, and impaired glucose tolerance may be associated with symptom severity. Elevated levels of plasma lactate have been detected in FM patients. Both pyruvate and lactate are produced in glucose metabolism and reflect oxidative metabolism. The objective of our study was to analyse disturbances in glucose, pyruvate, or lactate metabolism in FM patients. Methods: We measured plasma levels of glucose, pyruvate, and lactate during an oral glucose tolerance test in 40 non-diabetic, female FM patients and 30 age- and gender-matched healthy controls. Results: FM patients showed a higher glycaemic response to the glucose load at 1 hour (F [1, 68] = 10.4, P = .006) and 2 hours (F [1, 68] = 7.80, P = .02), and higher glucose area under the curve (13.8 [SD 2.92] vs 11.6 [SD 2.31], P < .01), than healthy controls. Group differences were explained by higher body mass index and percentage of smokers among the FM patients. Pyruvate and lactate levels were similar in both groups. Discussion: Impaired glucose regulation in FM patients is likely not due to FM itself, but to associated lifestyle factors. Our results highlight the importance of assessing the glucose regulation status and the lifestyle factors affecting glucose regulation in FM patients for prevention or early treatment of diabetes and associated complications. Trial Registration: ClinicalTrials.gov (NCT03300635)